[{"id":"e3b9b36a-b5ac-4b75-8870-c73ee1099884","acronym":"","url":"https://clinicaltrials.gov/study/NCT04325841","created_at":"2021-01-18T20:57:18.495Z","updated_at":"2024-07-02T16:36:05.504Z","phase":"Phase 2","brief_title":"Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children","source_id_and_acronym":"NCT04325841","lead_sponsor":"Beijing Boren Hospital","biomarkers":" ABL1 • CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["ABL1 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • autologous anti-CD19 (human derived) chimeric antigen receptor T cells • murine autologous anti-CD19 CART cells"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2022-08-15"}]